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AbstrAct
background Hospital-based data on the impact of 
socioeconomic environment on long-term survival after 
myocardial infarction (MI) are lacking. We compared 
outcome and quality of secondary prevention in 
patients after MI living in three different socioeconomic 
environments including patients from three tertiary-care 
teaching hospitals with similar service population size in 
Switzerland, Poland and Ukraine.
Methods This is a prospective cohort study of patients 
with a first MI in three different tertiary-care teaching 
hospitals in Bern (Switzerland), Gdansk (Poland) and Lutsk 
(Ukraine) during the acute phase in the year 2010 and 
follow-up of these patients with a questionnaire and, if 
necessary, telephone interviews 3.5 years after the acute 
event. The study cohort comprises all consecutive patients 
hospitalised in every one of the three study centres during 
the year 2010 for a first MI in the age ≤75 years who 
survived ≥30 days.
results The proportion of patients with ST-segment 
elevation myocardial infarction (STEMI) was high in 
Gdansk (Poland) (80%) and in Lutsk (Ukraine) (74%), while 
the ratio of STEMIs to non-STEMIs was nearly 50:50 in 
Bern (Switzerland) (50.6% STEMIs). Percutaneous coronary 
intervention (PCI) was the first choice therapy both in Bern 
(Switzerland) (100%) and in Gdansk (Poland) (92%), while 
it was not performed at all in Lutsk (Ukraine). We found 
substantial differences in treatment and also in secondary 
prevention interventions including cardiac rehabilitation. 
All-cause mortality at 3.5 year follow-up was 4.6% in Bern 
(Switzerland), 8.5% in Gdansk (Poland) and 14.6% in Lutsk 
(Ukraine).
conclusion Substantial differences in treatment and 
secondary prevention measures according to low-income, 
middle-income and high-income socioeconomic situation 
are associated with a threefold difference in mortality 
3.5 years after the acute event. Countries with low 
socioeconomic environment should increase efforts and be 
supported to improve care including secondary prevention 
in particular for MI patients. A greater number of PCIs 
per million inhabitants itself does not guarantee lower 
mortality scores.
IntroductIon
Cardiovascular diseases, frequently elicited 
by acute coronary syndromes (ACS), are the 
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Research
strength and limitations of the study
 ► Substantial differences in treatment and secondary 
prevention measures according to low-income, 
middle-income and high-income socioeconomic 
situation were found in Bern (Switzerland), Gdansk 
(Poland) and Lutsk (Ukraine) and are associated with 
a threefold difference in mortality 3.5 years after the 
acute event.
 ► Key strengths of this study are its prospective design 
comparing original data from patients in three 
distinctly different socioeconomic environments, 
the fact that our results are based on a direct 
comparison between single hospitals with similar 
service population, and similar compliance to 
guideline-recommended therapies and comparable 
research activities, but acting under three different 
economic situations, whereas interventions and 
outcome after acute coronary syndrome are usually 
compared in the framework of registry studies 
including single or various hospitals within countries 
(without clear definition of the catchment area and 
no convincing indication that the selected hospital 
population would be representative for the whole 
country).
 ► Limitations of this study are the fact that 
extrapolation of such local results to a whole country 
has still to be performed with caution, that we used 
information about the socioeconomic situation only 
on a region/country level but not on an individual 
level, that secondary outcomes are only patient 
reported and not validated by other sources, and that 
the reliability of the data in regard to medication and 
cardiac rehabilitation is somewhat compromised by 
the fact that a limited number of patients did not 
answer the follow-up questionnaire and could not be 
reached by telephone for an interview.
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leading cause of death worldwide.1 Over the past decades, 
numerous large-scale randomised clinical trials have demon-
strated the benefits of timely interventions for patients 
with ACS, including antiplatelet therapy, thrombolysis and 
urgent cardiac catheterisation followed by revascularisation 
as appropriate.2 The results of these trials have been incor-
porated in national and international guidelines providing 
treatment recommendations.3 4 Following these guidelines, 
the use of prehospital thrombolysis and percutaneous coro-
nary intervention (PCI), the appropriate prescription of 
adjunctive pharmacotherapy and referral to cardiac reha-
bilitation are now more widespread.5 Recent evidence 
suggests that this remarkable progress was associated with a 
significant decline in mortality from cardiovascular diseases 
over the last years, more pronounced in high-income 
regions (especially Australasia, Western Europe and North 
America6). Despite these well-established guidelines for 
the management of ACS, there are still strong differences 
with regard to the epidemiology, diagnostics and treatment 
of patients with ACS, leading to diverging morbidity and 
mortality rates across the globe. Not all reasons for these 
differences are well understood. Outcome variations can 
be caused by differences in the disease itself, baseline char-
acteristics of the population, treatment modalities, and in 
particular in the use of invasive cardiac procedures, or in any 
other unmeasured variable, such as socioeconomic charac-
teristics of the population.7 8 Interventions and outcomes 
after acute myocardial infarction (MI) in different areas 
and populations are usually compared in the framework 
of registries including various hospitals mostly within coun-
tries, whereas studies with direct comparison of treatment 
and outcome between single hospitals serving similar size 
populations in different socioeconomic environments are 
lacking.
The aim of this study was to compare interventions, 
secondary prevention and outcome in patients with acute 
MI between three different socioeconomic environments 
including patients from three tertiary-care teaching hospi-
tals with comparable service populations in Switzerland 
(high income), Poland (middle income) and Ukraine 
(low income).
Methods
Study design
This was a prospective cohort study with data analysis 
of patients with a first MI in three different tertiary-care 
teaching hospitals in Switzerland, Poland and Ukraine 
during the acute phase in the year 2010 and follow-up of 
these patients with a questionnaire and, if necessary, tele-
phone interviews 3 to 4 years after the acute event.
study centres
The participating study centres were three tertiary-care 
teaching hospitals: Bern University Hospital (Switzer-
land), Gdansk University Hospital (Poland) and Lutsk City 
Hospital (Ukraine). The service population is approxi-
mately 1 million inhabitants in Switzerland and in Poland 
and somewhat smaller in Ukraine. Population density in 
the service area is 171.4 persons/km2 for Bern University 
Hospital, 124 persons/km2 in the Pomeranian voivoship 
and 1805.5 persons/km2 in Gdansk, Gdynia and Sopot 
(Tricities as one agglomeration) for the Gdansk Univer-
sity Hospital and 51.5 persons/km2 in the Volyn region 
for the Lutsk City Hospital. All three centres have strict 
policies with regard to compliance with guideline-based 
therapies. All three centres are engaged in research and 
are participating in more than 10 clinical trials per year.
study population
This study included all consecutive patients hospitalised 
in one of the three study centres during the year 2010 
for a first MI at the age ≤75 years who survived ≥30 days. 
The definition of MI was either ST-segment elevation 
myocardial infarction (STEMI) or non-ST-segment eleva-
tion myocardial infarction (NSTEMI), both with elevated 
levels of troponin or creatine kinase-myocardial band 
(CK-MB) iso-enzyme.
Patient and treatment characteristics
The study centres prospectively collected data about 
age, gender, cardiovascular risk factors (body mass index 
(BMI), diabetes mellitus, arterial hypertension, hyper-
cholesterolaemia and smoking status) and significant 
comorbidities (chronic kidney disease, stroke, cancer, 
chronic lung disease). Data have been collected by dedi-
cated researchers in each hospital by chart review. Obesity 
has been defined as BMI ≥30, and smoker has been 
defined as former or current smoker.
Components of acute phase hospital treatment for 
MI were defined as fibrinolysis, PCI or drug treatment 
without intervention.
Furthermore, we obtained data about the medication 
at hospital discharge (antiplatelets, statins, ACE inhib-
itors (ACEIs) or angiotensin receptor blockers (ARBs), 
and β-blockers).
Follow-up evaluation
The follow-up evaluation was carried out in the years 
2013 and 2014 with a mean of 3.5 years after MI. All-cause 
mortality data were obtained from local or national regis-
tries. We sent questionnaires to all remaining patients 
with questions about rehospitalisation for any cardiovas-
cular disease event, participation in a structured cardiac 
rehabilitation programme and about adherence to 
secondary preventive medication (antiplatelets, statins, 
ACEIs or ARBs, and β-blockers). If the questionnaire was 
not returned within 3 weeks, we pursued an interview by 
telephone.
clinical outcomes
The primary endpoint of this study was all-cause mortality 
at 3.5 years of follow-up. Deaths were ascertained from 
the national registries for death reports.
Secondary endpoints were participation in a struc-
tured cardiac rehabilitation programme (stationary 
or ambulatory) and adherence to secondary 
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Table 1 Baseline characteristics of the study population in three different study centres in Bern (Switzerland), Gdansk 
(Poland) and Lutsk (Ukraine)
Bern 
(Switzerland)
547 patients
Gdansk 
(Poland)
375 patients
Lutsk 
(Ukraine)
164 patients p Value for all
Bern vs
Gdansk
Bern vs
Lutsk
Gdansk vs
Lutsk
Age 58.4±10.4 58.9±9.9 60.0±10.2 0.21 0.41 0.08 0.27
Women 26.5%
145/547
26.9%
101/375
33.5%
55/164
0.19 0.95 0.1 0.15
Smoking 49.4%
266/539
56.0%
197/352
35.6%
36/101
0.001 0.06 0.02 <0.001
DM 12.9%
68/527
22.3%
82/368
15.9%
26/164
<0.001 <0.001 0.41 0.11
Obesity 20.1%
109/541
33.0%
113/342
28.7%
47/164
<0.001 <0.001 0.03 0.37
Renal disease 5.1%
28/547
1.9%
7/375
2.0%
2/101
0.02 0.02 0.26 1
Lung disease 3.7%
20/547
3.5%
13/375
6.9%
7/101
0.25 1 0.21 0.21
Cancer 4.6%
25/547
1.3%
5/375
1.0%
1/101
0.009 0.01 0.16 1
Stroke 1.1%
6/547
1.3%
5/375
6.1%
10/164
<0.001 0.99 <0.001 0.005
STEMI 50.6%
277/547
79.9%
271/339
73.2%
120/164
<0.001 <0.001 <0.001 0.11
DM, diabetes mellitus; STEMI, ST-segment elevation myocardial infarction.
preventive medication (antiplatelets, statins, ACEIs or 
ARBs, β-blockers or diuretics).
The study had been approved by the regional ethical 
committees, and informed consent was obtained from 
the patients.
statistical analysis
Categorical variables were compared using the χ2 test. 
Continuous variables were expressed as mean value±SD 
and compared using one-way analysis of variance. Multiple 
logistic regression was used to examine impact of risk 
factors, comorbidities and treatments to 3.5 year mortality 
after MI. ORs with their 95% CIs were obtained. Statis-
tical analyses were performed with the use of R V.3.1.3 (R 
Foundation for Statistical Computing). All the statistical 
analyses were two-tailed. p values <0.05 were considered 
statistically significant, while Bonferroni corrections were 
applied for comparing each pair of groups.
results
Study population
The study population was drawn from three different 
tertiary-care hospitals in Switzerland, Poland and Ukraine, 
that is, 547 patients in Bern (Switzerland), 375 in Gdansk 
(Poland) and 164 in Lutsk (Ukraine) (table 1).
Table 1 shows the baseline characteristics of all included 
patients. The average age was comparable in all centres. 
The percentage of female patients was similar in all 
centres. The proportion of patients with STEMI was high 
in Gdansk (Poland) and in Lutsk (Ukraine), whereas the 
ratio of STEMI to NSTEMI was nearly 50:50 in Bern (Swit-
zerland). The distribution of all risk factors was lowest in 
Bern (Switzerland) except for the percentage of smokers, 
which was lowest in Ukraine due to a very low percentage 
of female smokers (7%) compared with male smokers 
(45%). Overall, the worst baseline risk profile was present 
in the patients from Gdansk (Poland). The higher stroke 
prevalence in Gdansk (Ukraine) compared with the other 
two study centres corresponds with the higher prevalence 
of stroke in the population.
In regard to comorbidities, the percentage of patients 
with renal disease was similar in Bern (Switzerland) and 
Lutsk (Ukraine) but was lower in Gdansk (Poland). Lung 
disease was most prevalent in Lutsk (Ukraine), while it was 
similar in Bern (Switzerland) and Gdansk (Poland). The 
incidence of cancer was low in all countries but highest in 
Bern (Switzerland), and the percentage of patients with 
previous stroke was highest in Lutsk (Ukraine), while it 
was similar in Bern (Switzerland) and Gdansk (Poland).
socioeconomic situation in bern (switzerland), Gdansk 
(Poland) and lutsk (ukraine)
The socioeconomic situation in the three participating 
countries is shown in table 2.
It is evident that the three participating countries 
represent three distinctly different levels of the socioeco-
nomic situation. This is true for the per capita income, 
the unemployment rate and for insurance coverage. 
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Table 2 Socioeconomic situation in Bern (Switzerland), Gdansk (Poland) and Lutsk (Ukraine) in 2010
Socioeconomic environment 
2010 Bern (Switzerland) Gdansk (Poland) Lutsk (Ukraine)
Per capita income €40 615/person/
year
€9300/person/year €1390/person/year
Unemployment rate 3.5% 5.5% 8.9%
Percentage of patients with ACS 
covered by insurance
100% 100% 5%
Data sources: Swiss Federal Statistical Office (www.bfs.admin.ch), Central Statistical Office of Poland (www.stat.gov.pl) and Ukraine 
Government Website (www.lutsk.ukrstat.gov.ua).
ACS, acute coronary syndrome.
Table 3 Hospital characteristics and services of three different study centres in Bern (Switzerland), Gdansk (Poland) and 
Lutsk (Ukraine)
Hospital/cardiology department 
structure 2010 Bern (Switzerland) Gdansk (Poland) Lutsk (Ukraine)
Carrying capacity 931 beds 950 beds 700 beds
Carrying capacity of the cardiology 
department
110 beds 83 beds 60 beds
Intensive care unit for patients with ACS Yes Yes Yes
Total no of MI patients 679 914 259
Total no of PCI 2273 2718 0
Total no of angiographies 4859 3910 0
Average duration of hospitalisation in 
patients with MI
3.3 days 7.8 days 14.1 days
Population density of catchment area 169.25 persons/km² 1757.35 persons/km² 5196 persons/km²
ACS, acute coronary syndrome; MI, myocardial infarction; PCI, percutaneous coronary intervention.
Unemployment rate according to national registries 
may have been underestimated due to the fact that not 
all unemployed persons are registered. In Bern (Switzer-
land) and Gdansk (Poland), almost all patients with MI 
were covered by insurance, but in Lutsk (Ukraine) the 
great majority was not.
hospital characteristics and services
Hospital characteristics and services are shown in table 3.
The care capacity of the cardiology department in 
Bern (Switzerland) was almost twice as large as the one in 
Lutsk (Ukraine). In the year 2010 in Lutsk City Hospital, 
facilities for coronary angiography and PCI were not 
available, whereas in Gdansk (Poland) most patients and 
in Bern (Switzerland) all patients fulfilling the inclusion 
criteria receive coronary angiography and, if considered 
to be appropriate, one or more stent implantations. The 
average duration of hospitalisation in ACS patients was 
inversely related to the socioeconomic situation.
treatment
Treatment modalities and medication at discharge in the 
three study centres are summarised in table 4.
Coronary angiography was performed in the acute 
phase in all patients fulfilling the inclusion criteria for 
this study in the study centre in Bern (Switzerland) and in 
almost all patients in Gdansk (Poland). PCI was the first 
choice therapy if indicated both in Bern (Switzerland) 
and in Gdansk (Poland), while it was not performed at 
all at the study centre in Lutsk (Ukraine) where some 
patients received fibrinolysis therapy. The remaining 
patients did not receive any reperfusion therapy at all in 
this Ukrainian centre.
At discharge, most patients were treated with anti-
platelets, statins, ACEIs or ARBs, and β-blockers in all 
three study centres. The prescription of ACEIs or ARBs 
at discharge was somewhat lower in Lutsk (Ukraine), 
whereas the prescription of β-blockers was consider-
ably higher in Bern (Switzerland) and Lutsk (Ukraine) 
compared with Gdansk (Poland).
Follow-up
Medication, cardiac rehabilitation attendance and 
all-cause mortality at follow-up are summarised in table 5.
The response rate was 84.3% in Switzerland and 61.6% 
in Poland, whereas in Gdansk (Poland) only 205/375 
patients (54%) agreed and took part at follow-up evalu-
ation sharing with us their data. In Bern (Switzerland), 
the use of antiplatelets, statins, ACEIs or ARBs, and 
β-blockers remained relatively high at follow-up. In 
Gdansk, there was a slight but significant decrease in the 
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Table 4 Acute treatment and medication at discharge in three different study centres in Bern (Switzerland), Gdansk (Poland) 
and Lutsk (Ukraine) (denominators in percentage)
Treatment
Bern 
(Switzerland)
Gdansk 
(Poland)
Lutsk 
(Ukraine)
p Value for 
all
Bern vs
Gdansk
Bern vs
Lutsk
Gdansk vs
Lutsk
Fibrinolysis 0% (547) 0% (375) 30.8% (164) <0.001 <0.001 <0.001
PCI 98% (547) 92.3% (375) 0% (164) <0.001 <0.001 <0.001 <0.001
Antiplatelet at discharge 100% (547) 100% (375) 97.2% (147) <0.001 0.002 0.006
Statin at discharge 97.6% (547) 97% (375) 94.6% (147) 0.153 0.602 0.054 0.169
ACEIs or ARB at discharge 89% (547) 88% (375) 81.6% (147) 0.052 0.628 0.016 0.058
β-Blocker at discharge 87.9% (547) 77.1% (375) 92.5% (147) <0.001 <0.001 0.116 <0.001
Comparisons between the three study centres with regard to fibrinolysis, PCI and medication.
ACEIs, ACE inhibitors; ARB, angiotensin receptor blocker; PCI, percutaneous coronary intervention.
Table 5 Medication, cardiac rehabilitation attendance and mortality at 3.5 year follow-up in in Bern (Switzerland), Gdansk 
(Poland) and Lutsk (Ukraine) (denominators in percentage)
Follow-up
Bern 
(Switzerland)
Gdansk 
(Poland)
Lutsk 
(Ukraine)
p Value 
for all
Bern vs
Gdansk
Bern vs
Lutsk
Gdansk vs
Lutsk
Antiplatelet at 
follow-up
98.3% (461) 83.9% (205) 78.2% (101) <0.001 <0.001 <0.001 0.223
Statin at follow-
up
90.9% (461) 78.5% (205) 31.7% (101) <0.001 <0.001 <0.001 <0.001
ACEIs or ARB 
at follow-up
73.3% (461) 81% (205) 34.7% (101) <0.001 0.034 <0.001 <0.001
β-Blocker at 
follow-up
74.4% (461) 81.5% (205) 52.5% (101) <0.001 0.047 <0.001 <0.001
Participation 
in cardiac 
rehabilitation
69.4% (343) 51.4% (204) 26% (92) <0.001 <0.001 <0.001 <0.001
3.5 year 
mortality
4.6% (547) 8.5% (375) 14.6% (164) <0.001 0.014 <0.001 0.033
Comparison between the three study centres in regard to follow-up medication, rehabilitation attendance and mortality.
ACEIs, ACE inhibitors; ARB, angiotensin receptor blocker.
use of antiplatelets, statins, ACEIs or ARBs (p<0.001 for 
decrease in antiplatelets and statins, p=0.022 for ACEIs 
or ARB), whereas the use of β-blockers increased slightly 
over time (p=0.217). In Lutsk (Ukraine), drug use 
decreased drastically (p<0.001 for decrease in the use of 
all drugs) and was significantly lower than in both other 
hospital populations.
The participation in any cardiac rehabilitation 
programme was highest in Bern (Switzerland) and 
lowest in Lutsk (Ukraine). In Bern (Switzerland), most 
patients have easy access to outpatient cardiac reha-
bilitation programmes and are referred to inpatient 
rehabilitation on request or if they are at increased risk or 
in need of intense surveillance and treatment. In Gdansk 
(Poland), only half of the patients have access to cardiac 
rehabilitation programmes mostly due to lack of insur-
ance coverage. In Ukraine, the cardiac rehabilitation 
system is in a transitional state. Although the old Soviet 
system with cardiac rehabilitation resorts (sanatoria) has 
neither shown to be effective in economical nor medical 
aspects, this system still exists. Lutsk City Hospital has a 
rehabilitation department with 20 beds for early reha-
bilitation after MI and stroke. Ten patients attended this 
inpatient rehabilitation programme, six patients were in 
sanatoria and eight patients attended an outpatient reha-
bilitation programme. Theoretically, all patients receive 
recommendations for self-rehabilitation and are regularly 
controlled by a cardiologist in an outpatient department 
in Lutsk (Ukraine).
All-cause mortality at 3.5 year follow-up was 4.6% in 
Bern (Switzerland), 8.5% in Gdansk (Poland) and 14.6% 
in Lutsk (Ukraine).
To find independent predictors of 3.5 year mortality, 
multivariate logistic regression analysis was performed. 
Lung disease (12.03 (2.16 to 67.11), p=0.005), renal 
disease (6.31 (1.63 to 24.5), p=0.008) and diabetes (7.6 
(2.58 to 22.38), p=0) were found to be mortality predic-
tors in Bern (Switzerland), whereas age (1.09 (1.02 to 
1.17), p=0.015) was found to be a mortality predictor in 
Gdansk (Poland). No single baseline parameter was found 
to predict mortality in Lutsk (Ukraine). Although the 
relation of STEMI versus non-STEMI varies significantly 
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Figure 1 Use of percutaneous coronary intervention (PCI), 
insurance coverage and 3.5 year mortality of patients with 
acute coronary syndromes in three study cities regions in 
Bern (Switzerland), Gdansk (Poland) and Lutsk (Ukraine).
between countries, this relation was not found to predict 
mortality in the three study centres (p=0.626 for Bern 
(Switzerland), p=0.379 for Gdansk (Poland) and p=0.802 
for Lutsk (Ukraine)).
dIscussIon
This prospective cohort study delivers important infor-
mation in regard to characteristics, management and 
outcomes of patients admitted for ACS (STEMI or 
NSTEMI) in three different socioeconomic environ-
ments in teaching hospitals in Bern (Switzerland) (high 
income), Gdansk (Poland) (middle income) and Lutsk 
(Ukraine) (low income) during the year 2010. The 
three participating hospitals are comparable in regard 
to their service population, to their compliance to follow 
guidelines (as demonstrated by the prescription of guide-
line-based drugs at discharge) and by their research and 
teaching activities. The main finding is a striking disparity 
of mortality at the 3.5 year follow-up: in Bern (Switzer-
land), mortality was 4.6%, while in Gdansk (Poland) it 
was nearly twofold with 8.5% and in Lutsk (Ukraine) 
almost threefold with 14.6%. Total mortality is inversely 
related to the socioeconomic status of the participating 
countries.
The two most important differences between the three 
hospital populations leading to these striking differ-
ences in total mortality are most probably the number 
of patients treated with PCI in the acute phase and the 
lack of insurance coverage during follow-up (figure 1). 
Besides lack of insurance, impaired socioeconomic 
situations with considerably lower budgets for health-
care services and lower income per capita are other 
important determinants for access to PCI and for long-
term compliance with medical therapies. However, an 
important finding is the fact that although acute PCI was 
only slightly less frequently applied in Gdansk (Poland), 
long-term mortality was still twofold in Gdansk (Poland) 
compared with Bern (Switzerland). Indeed, similar levels 
of access to PCI correspond to different medium-term to 
long-term mortality. This indicates that a greater number 
of PCI per million inhabitants do not guarantee lower 
mortality scores. Although we cannot exclude differ-
ences in acute intervention times and also in procedural 
success rates between the two countries as a contributing 
factor (because this has not been evaluated in this study 
population), this finding underlines the importance of 
secondary prevention interventions through comprehen-
sive cardiac rehabilitation.
It is apparent that the lower adherence to guidelines 
recommending early reperfusion therapy for patients 
with acute MI in Ukraine is not due to ignorance but 
rather the consequence of a difficult socioeconomic situ-
ation. In regard to medication prescription at discharge, 
the results from Ukraine indicate good adherence to 
actual guidelines.
Our study reflects the situation in the three countries in 
general. The number of PCI per 1 million inhabitants in 
2010 and 2011 was 506 in Switzerland, 735 in Poland and 
only 25 in Ukraine. The lower number of PCIs in Switzer-
land compared with Poland is due to a significant drop in 
the number of acute MIs in the country during the past 
few years, whereas the higher rate of NSTEMI compared 
with STEMI in Switzerland may indicate a greater number 
of heart attacks ‘only’ troponin positive. At the time of the 
study, there was no centre with capabilities for acute PCI 
in Lutsk, Ukraine; a first such centre was created in 2013 
and a second in 2015.
Another explanation for the significantly higher 
mortality in Gdansk (Poland) and Lutsk (Ukraine) 
compared with Bern (Switzerland) could be a worse base-
line risk profile or a higher incidence of comorbidities in 
patients of those two countries. Based on our multivar-
iate regression analysis, it is unlikely that such differences 
contribute to a great extent to the striking differences 
in 3.5 year mortality between the three study popula-
tions. Whereas lung disease, renal disease and diabetes 
were found to be mortality predictors in Bern (Switzer-
land) and age in Gdansk (Poland), neither baseline risk 
factors nor comorbidities were found to be predictors for 
3.5 year mortality in Lutsk (Ukraine). However, it cannot 
be excluded that this is due to the smaller sample size in 
Lutsk.
Orlandini et al7 found that several higher risk charac-
teristics were more common in lower-income countries 
and less common in higher-income countries. Jakobsen 
et al8 found that patients with low socioeconomic status 
were older and had a worse baseline risk profile than high 
SES and therefore argued that the poor outcome related 
to low socioeconomic status was primarily explained by 
differences in baseline characteristics, including higher 
comorbidity. Although we found some differences in base-
line characteristics, they fail to fully explain the striking 
gap in mortality between our three study areas. In partic-
ular, the average age and the percentage of females were 
nearly the same in all countries and the percentage of 
smokers was even lowest in Lutsk (Ukraine) (due to very 
low smoking rates in women). However, lung disease and 
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previous strokes were most prevalent in Lutsk (Ukraine) 
and obesity and diabetes were significantly more common 
in Gdansk (Poland) and Lutsk (Ukraine) compared with 
Bern (Switzerland). This explains mortality differences 
between our study populations only to a small extent.
The finding that mortality is inversely related to the 
socioeconomic status of each country is in line with some 
previous studies, such as Orlandini et al7 who found a 
large difference in the mortality rates, namely 12.1% in 
low-income countries and 4.9% in high-income countries. 
Furthermore, Rosvall et al9 obtained detailed information 
from patients after their first MI during the period 1993 
to 1996 on the use of revascularisation, cumulative house-
hold income and 5 year survival after the MI. They found 
that patients with the highest cumulative income under-
went a revascularisation procedure within 1 month after 
their first MI two to three times as often as patients with the 
lowest cumulative income and had half the risk of death 
within 5 years. Patients who underwent revascularisation 
showed a similarly lowered mortality risk in the different 
income groups, while there were strong socioeconomic 
differences in long-term mortality among patients who did 
not undergo revascularisation.10 11 Rosevall suggested that 
low socioeconomic position is associated with increased 
delays in seeking treatment and is an early determinant of 
major cardiovascular risk factors. Furthermore, it could 
be that those having a revascularisation are more likely to 
be followed up by a cardiologist and more likely to receive 
specific secondary prevention advice and a prescription 
for acetylsalicylic acid, β-blockers, ACEIs or statins.
An important question arises if the three hospi-
tal-based cohorts are representative for the populations 
of their respective countries. This is true for Bern/
Switzerland (with a service area comprising one large 
and some smaller cities, villages of different sizes, rural 
areas and mountain regions, a representative mix in 
regard to demographic characteristics and socioeco-
nomic situation, very similar medical services and 
identical insurance situation) and most likely true also 
for Gdansk/Poland (representative demographic and 
socioeconomic situation of the service population, one 
national insurance payer covering costs of all MIs in 
public and private hospitals with identical sets of proce-
dures and requirements and similar results of recent 
outcome analyses performed in the years 2009–2014 
by the National Institute of Public Health with small 
differences in 1 and 3 year mortality between the refer-
ence university hospitals). However, for Lutsk, the 
comparison is more complicated for Ukraine, being a 
country in transition typically with greater fragmenta-
tion within the country. In 2010, however, when patients 
entered this study, Ukraine had only 25 PCI/1 million 
inhabitants in comparison to 506 (Switzerland) and 
735 (Poland)/1 million inhabitants; as the number for 
PCIs in Ukraine has been very small overall, it seems 
unlikely that this has led to important differences in ACS 
mortality between different regions of Ukraine, perhaps 
with the exception of somewhat lower mortality in the 
capital city Kiev. Nevertheless, after 2010, the number of 
PCIs increased steadily and substantially, which can be 
seen in the context of the ‘Stent for Life’ initiative.
Widimsky et al12 first suspected that medical and 
non-medical staff are the main barriers for wider primary 
PCI implementation: low staffing levels are often related 
to conservative attitudes of physicians and to insufficient 
motivation of medical staff to run demanding non-stop 
PCI services for ACS. However, such an argument was not 
pertinent to Lutsk City Hospital, Ukraine, where no cath-
eter laboratory was available at the time. In a follow-up 
study of the former survey of Widimsky et al, Kirstensen 
et al13 assumed that one possible explanation for the 
observed variations could be the countries’ disparate reim-
bursement schemes. This is in line with our survey that 
showed big differences in the reimbursement schemes. In 
Switzerland and Poland, almost all patients with ACS are 
covered by insurance, but in Ukraine, more than 95% are 
not. There is no obligatory medical insurance in Ukraine. 
A voluntary medical insurance (VMI) system is only devel-
oping in this country. Experts consider that not more 
than 5% of Ukrainians are covered by this kind of insur-
ance14 and expenses related to VMI represent less than 
1% among sources of revenue of total expenditure on 
healthcare in Ukraine.15 Kirstensen et al13 found that the 
scant evidence within the field indicates that the barriers 
for PCI implementation are a complex mix of medical, 
organisational, patient-related, regulatory and economic 
factors. Furthermore, they suggested that major efforts 
are highly necessary to increase public knowledge on 
the symptoms of ACS and of the awareness for imme-
diate contact to the emergency medical system in order 
to shorten patient delay. Nevertheless, prehospital delays 
(229 min in Poland and 240 min in Switzerland) and door-
to-needle time in patients undergoing invasive treatment 
(around 25 min over the study period in both countries) 
cannot explain the difference in mortality between the 
two countries.
Differences in hospital characteristics and services are 
also important. In the year 2010, at the index hospital in 
Ukraine, angiographies or PCIs were not performed in 
acute MI, while in Poland the index hospital performed 
3910 and in Switzerland even 4859 angiographies. The 
average duration of hospitalisation was shortest in Bern 
(Switzerland) with 3.3 days and longest in Lutsk (Ukraine) 
with 14.1 days, which indicates that the treatment dura-
tion within the hospital does not improve the prognosis 
under these circumstances.
In addition, Laut et al found a correlation between the 
availability of physicians and increase in PCI utilisation. 
Countries with both low and high population density 
per square kilometre had a slower increase in PCI utili-
sation for ACS compared with countries with a medium 
population density. They assumed that differences in 
utilisation rates of PCI for ACS could partly be explained 
by the countries’ supply factors such as the number of 
physicians and number of acute care beds, rather than 
financial factors.16 17
group.bmj.com on February 7, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Kämpfer J, et al. BMJ Open 2017;7:e012715. doi:10.1136/bmjopen-2016-012715
Open Access 
Furthermore, Puymirat et al18 suggested that one of 
the key determinants of improved outcomes is the imple-
mentation of regional networks, which is now strongly 
advocated in the most recent European Society of Cardi-
ology guidelines.
The use of guideline-recommended medications at 
discharge was relatively high in all three countries, but still 
there were some differences. Nearly all patients received 
antiplatelets and statins at discharge, while ACEIs or 
ARBs and β-blockers were prescribed to 80%–90% of 
all patients in all three hospitals. However, an important 
difference between patients from these three countries 
is the adherence to guideline-recommended medications 
during follow-up. After 3.5 years of follow-up, in Lutsk 
(Ukraine) only 78.2% of patients were on antiplatelets 
and only 31.7% on statins. This circumstance may play 
a significant role for mortality differences. Low compli-
ance to medical treatment after MI is a complex issue and 
financial problems may play a key role. The striking differ-
ence in income per capita, reimbursement and insurance 
coverage in Ukraine compared with Switzerland and 
Poland engenders a big financial burden to Ukrainian 
patients who have to pay for each drug themselves.
The participation in a cardiac rehabilitation programme 
was highest in Bern (Switzerland) with 69% and lowest in 
Lutsk (Ukraine) with 26%. Despite the fact that secondary 
prevention through cardiac rehabilitation is a guide-
line-recommended treatment modality that improves 
morbidity and mortality in patients after acute MI,19–21 
there are obviously still large differences among the three 
countries mainly because participation in cardiac reha-
bilitation is recommended, but availability is limited in 
Poland and Ukraine. In Poland, there is restricted access 
for most patients to such programmes. The only public 
and obligatory health insurer, that is, the National Health 
Fund, covers all costs of modern in-hospital acute MI 
therapy, but has limited resources for post-MI cardiac 
rehabilitation. In 2009, only 22% of all patients with 
post-MI in Poland underwent modern comprehensive 
cardiac rehabilitation.22 This indicates that secondary 
prevention is underestimated and underfinanced by 
decision makers. Whereas statin usage increased largely 
during the last decade in Poland, no significant changes 
in dietary habits were observed during this period.23 In 
Lutsk (Ukraine), theoretically all patients receive recom-
mendation for self-rehabilitation with periodical controls 
by a cardiologist in the outpatient department, and there 
are some limited opportunities to attend outpatient or 
inpatient rehabilitation programmes. However, access 
to comprehensive ambulatory cardiac rehabilitation is 
highly restricted due to socioeconomic factors.
While making cross-country comparisons is challenging, 
the results of this study nevertheless are instructive in 
presenting a picture of the striking variation of the inva-
sive and medical management of patients with ACS in 
three European countries. The main obstacle limiting 
analyses of healthcare utilisation and outcomes is the lack 
of a sound scientific European database on PCI and ACS. 
Good-quality data are a necessity for identifying barriers 
and an instrument to target goals, as well as for moni-
toring and evaluating treatment use, quality of care and 
effects. In an attempt to reduce differences in a number 
of European countries, the Stent for Life initiative, 
supporting the implementation of timely PCI, was estab-
lished in 2008.24 25 The participating countries reported 
significant rises in PCI utilisation, reduction in mortality 
and an overall more effective management of the STEMI 
treatment system. This strongly calls for a continuation of 
a strategy of implementation and for support of countries 
with yet low activities, such as Ukraine.26 27
A major strength of this study is its prospective design 
comparing original data from patients in three distinctly 
different socioeconomic environments and the fact that 
our results are based on a direct comparison between 
single hospitals with similar service population, similar 
compliance to guideline-recommended therapies and 
comparable research activities, but acting under three 
different economic situations. In contrast, interna-
tional comparison studies are usually performed in the 
framework of registry studies including single or various 
hospitals within countries but without clear definition of 
the catchment area and no convincing indication that the 
selected hospital population would be representative for 
the whole country.
limitations
Extrapolation of such local results to a whole country 
has to be performed with caution. Whereas there is little 
variation in treatment modalities of patients with MI in 
Switzerland and only slightly more variation in Poland, 
there was a great heterogeneity in Ukraine in the year 
2010. Furthermore, PCI for ACS has also been fostered in 
Ukraine during the past few years and therefore mortality 
from acute MI may have decreased since. Information 
about the socioeconomic situation was used only on a 
regional/country level but not on an individual level. 
Secondary outcomes are only patient reported and not 
validated by other sources. In regard to follow-up data, 
the reliability of the data in regard to medication and 
cardiac rehabilitation is somewhat compromised by the 
fact that a limited number of patients did not answer the 
follow-up questionnaire and could not be reached by tele-
phone for an interview.
conclusIons
In conclusion, we found striking disparities in mortality 
in patients during a follow-up of 3.5 years between the 
three study populations. Mortality was almost twofold 
higher in Gdansk (Poland) and threefold higher in Lutsk 
(Ukraine) compared with Bern (Switzerland). These 
differences could not be explained by worse baseline 
risk profile or higher incidence of comorbidities and 
therefore is probably mainly due to socioeconomic differ-
ences between the three countries. In addition, a greater 
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number of PCIs per million inhabitants itself does not 
guarantee lower mortality scores.
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